BMS’s Revlimid Loss Of Exclusivity Is Not As Bad As Expected, But Not For Long
The company credited generics’ late market entry, but that benefit is not expected to last; the firm lowered guidance for annual sales of the oncologic.
You may also be interested in...
The company said screening and diagnosis were still below pre-pandemic levels, but Biktarvy and Descovy brought HIV sales back into positive territory.
Even without Lagevrio, Merck's base business grew by double digits; the company raised its revenue guidance for the year.
Nektar/BMS Deal Takes Second Gut Punch As IL-2/PD-1 Combo Goes Down In Flames